Quantcast
Home > Quotes > XLRN
XLRN

Acceleron Pharma Inc. Common Stock (XLRN) Quote & Summary Data

$36.97
*  
0.16
0.43%
Get XLRN Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading XLRN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    XLRN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 37.46 / $ 36.50
Share Volume
421,461
50 Day Avg. Daily Volume
299,768
Previous Close
$ 36.81
52 Week High / Low
$ 46.93 / $ 29.35
Market Cap
1,692,313,765
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
421,461
50 Day Avg. Daily Volume:
299,768

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.62

Trading Range

The current last sale of $36.97 is 25.96% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 37.46 $ 46.93
 Low: $ 36.50 $ 29.35

Company Description (as filed with the SEC)

We are a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have generated several innovative therapeutic candidates, all of which encompass novel potential first-in-class mechanisms of action. We have focused and prioritized our research and development activities within three key therapeutic areas: hematologic, neuromuscular and pulmonary. If successful, these candidates could have the potential to significantly improve clinical outcomes for patients across these areas of high, unmet need.  ... More ...  

Risk Grade

Where does XLRN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 36.56
Open Date:
Jun. 19, 2018
Close Price:
$ 36.81
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info